Par Drugs [PAR] vs Bal Pharma [BALPHARMA] Detailed Stock Comparison
Par Drugs
NSE
Loading...
Bal Pharma
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Par Drugs wins in 13 metrics, Bal Pharma wins in 5 metrics, with 0 ties. Par Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Par Drugs | Bal Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.15 | 20.03 | Par Drugs |
| Price-to-Book Ratio | 1.37 | 2.31 | Par Drugs |
| Debt-to-Equity Ratio | 0.00 | 196.55 | Par Drugs |
| PEG Ratio | N/A | -1.07 | N/A |
| EV/EBITDA | 5.55 | 9.42 | Par Drugs |
| Profit Margin (TTM) | 13.23% | 2.43% | Par Drugs |
| Operating Margin (TTM) | 6.75% | 5.37% | Par Drugs |
| EBITDA Margin (TTM) | 6.75% | 5.37% | Par Drugs |
| Return on Equity | 14.47% | 9.32% | Par Drugs |
| Return on Assets (TTM) | 8.97% | 2.15% | Par Drugs |
| Free Cash Flow (TTM) | $149.34M | $15.28M | Par Drugs |
| Dividend Yield | N/A | 1.20% | N/A |
| 1-Year Return | -57.75% | -33.65% | Bal Pharma |
| Price-to-Sales Ratio (TTM) | 1.34 | 0.49 | Bal Pharma |
| Enterprise Value | $1.08B | $2.81B | Bal Pharma |
| EV/Revenue Ratio | 1.07 | 0.95 | Bal Pharma |
| Gross Profit Margin (TTM) | 56.21% | 49.08% | Par Drugs |
| Revenue per Share (TTM) | $82 | $188 | Bal Pharma |
| Earnings per Share (Diluted) | $10.86 | $4.51 | Par Drugs |
| Beta (Stock Volatility) | -0.39 | 0.23 | Par Drugs |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Par Drugs vs Bal Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Par Drugs | -4.34% | 10.79% | 5.36% | 10.86% | 9.92% | -47.57% |
| Bal Pharma | 0.00% | 2.21% | -2.42% | -15.24% | 10.62% | -28.20% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Par Drugs | -57.75% | -32.88% | 340.73% | 119.47% | 119.47% | 119.47% |
| Bal Pharma | -33.65% | -6.55% | 94.03% | 27.30% | 151.94% | 55.32% |
News Based Sentiment: Par Drugs vs Bal Pharma
Par Drugs
News based Sentiment: MIXED
The month presented a mixed bag for Par Drugs, with a significant increase in profit after tax alongside declining operating profit and continued stock underperformance. The upcoming AGM is a key event, but the overall picture is uncertain, making it a moderately important month for investors.
Bal Pharma
News based Sentiment: NEGATIVE
The month was dominated by disappointing Q1 financial results, showing significant declines in revenue and profit. While strategic initiatives like a potential merger and ESOP plan were considered, the overall narrative is one of short-term challenges and uncertainty, making it a significant month for investors to assess the company's direction.
Performance & Financial Health Analysis: Par Drugs vs Bal Pharma
| Metric | PAR | BALPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.36B | ₹1.44B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 14,047 | 20,027 |
| 90 Day Avg. Volume | 8,813 | 18,672 |
| Last Close | ₹108.64 | ₹90.32 |
| 52 Week Range | ₹81.01 - ₹348.45 | ₹78.06 - ₹140.95 |
| % from 52W High | -68.82% | -35.92% |
| All-Time High | ₹348.45 (Dec 02, 2024) | ₹167.90 (Jan 11, 2016) |
| % from All-Time High | -68.82% | -46.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | -0.11% |
| Quarterly Earnings Growth | -0.56% | -0.23% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.02% |
| Operating Margin (TTM) | 0.07% | 0.05% |
| Return on Equity (TTM) | 0.14% | 0.09% |
| Debt to Equity (MRQ) | 0.00 | 196.55 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹80.33 | ₹39.09 |
| Cash per Share (MRQ) | ₹22.38 | ₹6.82 |
| Operating Cash Flow (TTM) | ₹161.60M | ₹74.55M |
| Levered Free Cash Flow (TTM) | ₹120.93M | ₹72.15M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.20% |
| Last 12-Month Dividend | ₹0.00 | ₹1.20 |
Valuation & Enterprise Metrics Analysis: Par Drugs vs Bal Pharma
| Metric | PAR | BALPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.15 | 20.03 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -1.07 |
| Price to Sales (TTM) | 1.34 | 0.49 |
| Price to Book (MRQ) | 1.37 | 2.31 |
| Market Capitalization | ||
| Market Capitalization | ₹1.36B | ₹1.44B |
| Enterprise Value | ₹1.08B | ₹2.81B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.07 | 0.95 |
| Enterprise to EBITDA | 5.55 | 9.42 |
| Risk & Other Metrics | ||
| Beta | -0.39 | 0.23 |
| Book Value per Share (MRQ) | ₹80.33 | ₹39.09 |
Financial Statements Comparison: Par Drugs vs Bal Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PAR | BALPHARMA |
|---|---|---|
| Revenue/Sales | ₹223.30M | ₹818.76M |
| Cost of Goods Sold | ₹97.77M | ₹439.73M |
| Gross Profit | ₹125.53M | ₹379.04M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹15.09M | ₹54.60M |
| EBITDA | ₹32.18M | ₹87.24M |
| Pre-Tax Income | ₹22.79M | ₹25.93M |
| Income Tax | ₹6.28M | ₹-28.25M |
| Net Income (Profit) | ₹16.51M | ₹54.19M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PAR | BALPHARMA |
|---|---|---|
| Cash & Equivalents | ₹275.77M | ₹17.52M |
| Total Current Assets | ₹548.61M | ₹2.35B |
| Total Current Liabilities | ₹165.69M | ₹2.20B |
| Long-Term Debt | ₹0 | ₹314.13M |
| Total Shareholders Equity | ₹989.75M | ₹774.04M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹389.15M | ₹709.91M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PAR | BALPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PAR | BALPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 14,047 | 20,027 |
| Average Daily Volume (90 Day) | 8,813 | 18,672 |
| Shares Outstanding | 12.30M | 15.92M |
| Float Shares | 2.67M | 5.30M |
| % Held by Insiders | N/A | 0.65% |
| % Held by Institutions | N/A | 0.00% |
Dividend Analysis & Yield Comparison: Par Drugs vs Bal Pharma
| Metric | PAR | BALPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.20 |
| Last 12-Month Dividend Yield | N/A | 1.20% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹1.07 |
| 3-Year Avg Dividend Yield | N/A | 1.01% |
| 3-Year Total Dividends | ₹0.00 | ₹3.20 |
| Ex-Dividend Date | N/A | Sep 17, 2024 |